ClinicalTrials.gg
RecruitingNCT06823752Neuro-DORAUpdated Sep 18, 2026

A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.

A Phase 2 interventional study of Lemborexant 10 MG and Placebo in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Woolcock Institute of Medical Research · Phase 2, Interventional, and Other

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, none of them phase 3. lemborexant · Sleep Initiation and Maintenance Disorders.

Planned enrollment
20th of 21
20 · median 82
Started
2025
with 3 others
Phase 2
8 of 21
5 open now
Registered
16th of 21
by date
Lead sponsor
1 of 21
Woolcock Institute of Medical Research

Among the 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders, this one is the 20th largest by planned enrollment, is one of 4 that started in 2025, is one of 8 in phase 2, and was the 16th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

8 of the 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lemborexant

lemborexant: first FDA approval 2019 (DAYVIGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing lemborexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia. The main questions it aims to answer are:

  • Does the DORA reduce blood-based phosphorylated TAU181, in adults with insomnia, when compared to placebo
  • Does the DORA reduce other blood-based biomarkers of neurodegeneration, including phosphorylated TAU217, amyloid beta 40:42 ratio, Neurofilament Light Chain (NFL) and Glial Fibrillary Acidic Protein (GFAP), when compared to placebo.

Participants will:

  • Take 10mg Lemborexant nightly for two weeks
  • Take a matching placebo nightly for two weeks
  • Visit the research institute for a screening visit and for an overnight visit at the conclusion of each study drug treatment (3 visits in total).
Read the detailed description

This is a randomised placebo-controlled cross-over study of a dual orexin receptor antagonist (DORA) versus placebo in adults with insomnia.

To be enrolled in the study, participants are required to complete an online pre-screening survey. Eligible participants will be directed to a separate webpage where they will be invited to review and download the Participant Information Sheet (PIS) and asked to provide their contact details and consent for a follow up call/email from the research team to book in a screening visit. At the screening visit the study team will explain the study to each participant and ensure they have had ample time prior to the visit to read and understand the PIS and have had the opportunity to ask any questions. The consent form will be signed by both the participant and a medical officer and participants will be randomised into their first treatment period; DORA (Lemborexant) or placebo.

Participants will take the treatment orally, nightly for 2 weeks. There will be a 2-4 week washout period between treatments. At the conclusion of both two-week treatment phases, participants will attend the laboratory for an overnight visit. The visit will take approximately 18 hours (including sleep time). During this visit, participants will partake in a number of assessments including HD-EEG, fNIRS, questionnaires and pupillometry. Participants will also have blood samples collected in the morning of the overnight study (hourly for four hours).

The study will recruit primarily through social media advertisements. The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.

03

Conditions studied

  • Insomnia

Keywords

  • DORA
  • Tau
  • Beta Amyloid
  • Dementia
  • Sleep
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of insomnia disorder as defined by the (difficulty initiating or maintaining sleep or waking up too early for at least 3 nights per week, for at least 3 months, with adequate opportunity and circumstances for sleep and at least one daytime impairment related to the sleep difficulty) and a score ≥15 on the ISI.
  • Able to provide informed electronic consent.
  • Fluent English literacy.
  • Adults aged between 40-65 years.

Exclusion criteria

Exclusion Criteria:

  • People highly dependent on medical care as determined by a medical officer.
  • Untreated moderate-severe sleep apnoea as diagnosed using in-home wrist oximetry (oxygen desaturation index>15, ongoing effectively treated sleep apnoea with insomnia will be allowed).
  • Circadian disorders, narcolepsy, severe restless legs syndrome, and REM sleep behaviour disorder or uncontrolled psychiatric disorders.
  • History of attempted suicide or current suicide ideation (indicated by a score >0 on Q9 of the Patient Health Questionnaire-9) at pre-screening.
  • Objective cognitive decline measured by scoring ≤26 on the (MoCA)
  • Regular shift work, jet lag or trans-meridian travel (over 2h time difference) in the past week before randomisation.
  • Pregnancy or lactation. Women will be advised to use for the duration of the study and a urine pregnancy test will be performed when necessary.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with clinical study procedures.
  • Currently participating in or has participated in a research study of an agent or device within 4 weeks of enrolment.
  • Concomitant use of medicines that are inhibitors (e.g., diltiazem, fluvoxamine, fluconazole, itraconazole, verapamil), or moderate to strong inducers of (e.g., carbamazepine, modafinil, phenytoin, rifampicin, St John's Wort)
  • Ongoing use of anti-psychotic medication, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine or illicit stimulants.
  • Regular use of hypnotics (including melatonin, valerian, kava, benzodiazepines and Z-drugs), and other medications that can cause additive sedation (e.g. sedating antihistamines, tricyclic antidepressants, antipsychotics) within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Regular use of psychostimulants (e.g., dexamfetamine, lisdexamfetamine, methylphenidate) or non-amphetamine psychostimulants (e.g., armodafinil, modafinil, atomoxetine) within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Use of antidepressant medications for treatment of low mood for less than one year or dose changes (escalation or tapering) or change in antidepressant medications within the past year.
  • Regular use opioids within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Ongoing use of THC- or CBD-containing products within 14 days prior to the start of the trial.
  • Dependence or any other drug or alcohol dependence within the past two years (alcohol to be limited to no more than 2 standard drinks per day during trial period).
  • Allergy to lactose.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Dual Orexin Receptor Antagonist (DORA)

    10mg Lemborexant tablet taken orally, nightly for two weeks

    Drug: Lemborexant 10 MG

  • Placebo comparator
    Placebo

    Matching placebo tablet taken orally, nightly for two weeks

    Drug: Placebo

Interventions

  • An orally ingested tablet containing 10mg Lemborexant taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.

    Also known as: Dayvigo

  • DrugPlacebo

    Placebo tablets will contain similar excipients without the active ingredient (Lemborexant) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.

06

What researchers measure

Primary outcomes

  1. Blood levels of TAU181

    Morning blood-based phosphorylated TAU (standardised pTAU181:TAU181 ratio)

    Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.

Secondary outcomes

  1. Blood levels of TAU217

    Morning blood-based phosphorylated TAU217, analysed within each participant.

    Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.

  2. Blood levels of Beta amyloid

    Morning blood-based Beta Amyloid 40:42 ratio, analysed within each participant.

    Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.

  3. Blood levels of NFL

    Morning blood-based Neurofilament Light Chain (NFL), analysed within each participant.

    Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.

  4. Blood levels of GFAP

    Morning blood-based Fibrillary Acidic Protein (GFAP), analysed within each participant.

    Time frame: 5 samples hourly for 4 hours after awakening in the morning of the overnight treatment period visits (approximately 7am-11am). We will test whether there is a difference between treatments over the time period.

Other outcomes

  1. Absolute Electroencephalographic (EEG) Power During Non-Rapid Eye Movement (NREM) (stages 2 and 3) and REM sleep.

    High-density EEG, spectral power for frequency ranges low-delta: 0.5-1 Hz; delta: 1-4.5 Hz; theta: 4.5-8Hz; alpha: 8-12Hz; sigma: 12-15 Hz; beta: 15-25 Hz; gamma: 25-40 Hz. Absolute Electroencephalographic (EEG) Power During Non-Rapid Eye Movement (NREM) and REM sleep (12 statistical comparisons). Unit of measurement is μV\^2.

    Time frame: 14th night after treatment starts.

07

Study locations

1 of 1 sites recruiting
  • Woolcock Institute of Medical Research
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
    • Grigori Kaplan, PhD · Contactgrigori.kaplan@sydney.edu.au · +61 9114 0412
    • Camilla Hoyos, PhD · Principal investigator
    • Brendon Yee, PhD FRACP · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will be available for ten years.

Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the WIMR through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Contact the Coordinating Principal Investigator for access to data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 12, 2025
StartActual
May 13, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06823752
Lead sponsor
Woolcock Institute of Medical Research
Responsible party
Camilla Hoyos (Research Leader, Woolcock Institute of Medical Research) — Principal investigator
First posted
Feb 12, 2025
Start date
May 13, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Camilla Hoyos, MPH, PhD
Contact
camilla.hoyos@mq.edu.au
0438801044
Rhearne Ryan, HScHons, PhD
Contact
rhearne.ryan@woolcock.org.au
+61 2 9805 3274
Camilla Hoyos, MPH, PhD
principal investigator · Woolcock Institute of Medical Research
Brendon Yee, MBChB, FRACP, FCCP, PhD
principal investigator · Woolcock Institute of Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemborexant

Start the discussion